Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies

Acta Pharmacologica Sinica
Matthew E SloanBernard Le Foll

Abstract

Endocannabinoid signaling is implicated in an array of psychopathologies ranging from anxiety to psychosis and addiction. In recent years, radiotracers targeting the endocannabinoid system have been used in positron emission tomography (PET) studies to determine whether individuals with psychiatric disorders display altered endocannabinoid signaling. We comprehensively reviewed PET studies examining differences in endocannabinoid signaling between individuals with psychiatric illness and healthy controls. Published studies evaluated individuals with five psychiatric disorders: cannabis use disorder, alcohol use disorder, schizophrenia, post-traumatic stress disorder, and eating disorders. Most studies employed radiotracers targeting cannabinoid receptor 1 (CB1). Cannabis users consistently demonstrated decreased CB1 binding compared to controls, with normalization following short periods of abstinence. Findings in those with alcohol use disorder and schizophrenia were less consistent, with some studies demonstrating increased CB1 binding and others demonstrating decreased CB1 binding. Evidence of aberrant CB1 binding was also found in individuals with anorexia nervosa and post-traumatic stress disorder, but limited data have be...Continue Reading

References

Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M HerkenhamK C Rice
Jun 1, 1990·The American Journal of Psychiatry·N D VolkowD Christman
Apr 1, 1994·Archives of General Psychiatry·D H LinszenM E Lenior
May 5, 1998·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·G ColomboG L Gessa
Mar 25, 1999·Psychopharmacology·M HaneyM W Fischman
Sep 29, 1999·Neuroreport·F M LewekeD Piomelli
Sep 13, 2003·Lipids in Health and Disease·Nicola De MarchiVincenzo Di Marzo
Jun 1, 2004·The American Journal of Psychiatry·Herbert Y MeltzerUNKNOWN Meta-Trial Study Group
Jun 3, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Deepak Cyril D'SouzaJohn Harrison Krystal
Nov 5, 2004·The Journal of Pharmacology and Experimental Therapeutics·Bernard Le Foll, Steven R Goldberg
Nov 18, 2005·The New England Journal of Medicine·Jean-Pierre DesprésUNKNOWN Rimonabant in Obesity-Lipids Study Group
Feb 16, 2006·JAMA : the Journal of the American Medical Association·F Xavier Pi-SunyerUNKNOWN RIO-North America Study Group
May 5, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Abraham ZangenRoy A Wise
May 31, 2007·Proceedings of the National Academy of Sciences of the United States of America·H Donald BurnsRichard J Hargreaves
Nov 17, 2007·BMJ : British Medical Journal·Diana RuckerDavid C W Lau
Feb 29, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Zuzana JustinovaSteven R Goldberg
May 16, 2008·Journal of Clinical Psychopharmacology·Michael SoykaUNKNOWN ACTOL Study Investigators
Dec 17, 2008·Current Pharmaceutical Design·Andrew G Horti, Koen Van Laere
Sep 12, 2009·European Journal of Endocrinology·Vincenzo Di MarzoMarja-Riitta Taskinen
Oct 29, 2009·Alcoholism, Clinical and Experimental Research·Teresa FemeníaJorge Manzanares
Dec 17, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Garth E TerryRobert B Innis
Dec 25, 2010·Therapeutic Advances in Gastroenterology·Rita Brun, Braden Kuo
Feb 10, 2011·Brain : a Journal of Neurology·Karolien GoffinKoen Van Laere
Feb 12, 2011·Drug and Alcohol Dependence·Frances R LevinEdward V Nunes
Mar 25, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Antonio Ortega-AlvaroJorge Manzanares
Apr 5, 2011·Neurobiology of Aging·Koen Van LaereWim Vandenberghe
Jul 2, 2011·Biological Psychiatry·Nathalie GérardKoen Van Laere
Jul 22, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Matthew N HillCecilia J Hillard
Jul 26, 2011·Nature Neuroscience·Zheng-Xiong XiEliot L Gardner
Aug 17, 2011·International Journal of Obesity : Journal of the International Association for the Study of Obesity·B Gatta-CherifiD Cota
Aug 27, 2011·American Journal of Epidemiology·Yann Le Strat, Bernard Le Foll

❮ Previous
Next ❯

Citations

Jan 8, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Laura M BestIsabelle Boileau
Jun 6, 2019·Frontiers in Nutrition·Martha A Schalla, Andreas Stengel
Dec 22, 2020·Journal of Internal Medicine·C J Fowler
May 21, 2020·Physics in Medicine and Biology·Paul LecoqMathieu Benoit
Feb 26, 2021·Nature Reviews. Disease Primers·Jason P ConnorWayne D Hall
Mar 4, 2021·Reviews in the Neurosciences·Tomasz BielawskiDorota Frydecka
Sep 2, 2020·Trends in Molecular Medicine·Terri A deRoon-CassiniCecilia J Hillard
Jun 20, 2020·ACS Chemical Neuroscience·Cassis VarlowNeil Vasdev

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapies

Software Mentioned

OMAR

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Alcohol Use Disorder

Alcohol use disorder involves a pattern of alcohol consumption that includes compulsive use and a loss of control over intake of alcohol. The impact on physical health, socioeconomic factors, and psychiatric health is profound. Find the latest research on alcohol use disorder here.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.